Fig. 1.

CD154 blockade and DST prolongs SG survival. (A) Mice were adoptively transferred with 1.5 × 10⁶ of each OT-I and OT-II T cells 2 d before transplantation. On day 0, mice were transplanted with mOVA SG and were treated with 10⁷ mOVA DST and/or 500 μg of MR-1 where indicated. (B) Untreated mice rejected SGs with an MST of 13.5 d. Anti-CD154 monotherapy led to bimodal survival of SGs, with 50% of mice rejecting grafts with an MST of 15 d and 50% demonstrating indefinite survival (P = 0.0027). DST monotherapy resulted in to an MST of 18 d (P = 0.031), whereas combined anti-CD154/DST led to an indefinite survival of SGs (P < 0.0001). Data are cumulative of two independent experiments with five mice per group.